Literature DB >> 8452705

[The usefulness of reactive protein C in managing patients with ulcerative colitis and Crohn's disease].

A J López Morante1, F Sáez-Royuela, L Yuguero del Moral, J L Martín Lorente, C Ojeda Giménez.   

Abstract

Serum concentrations of C-Reactive protein (CRP) were measured in 40 patients with inflammatory bowel disease (22 with ulcerative colitis and 18 with Crohn's disease). In the evaluation of disease activity, CRP was a more sensitive (98.6% vs 71.4%) and specific (95% vs 84.6%) activity index in Crohn's disease than in ulcerative colitis. The CRP concentrations were significantly higher in Crohn's disease (57.7 +/- 55.7 mg/dl) than in ulcerative colitis (16.3 +/- 18.8 mg/dl), particularly in severely affected patients (104.8 +/- 54.3 vs 29 +/- 24.2 mg/dl). The CRP levels correlated significantly with clinical activity indices. There was poor or no correlation between CRP levels and the endoscopic activity indices, the extent of inflammatory bowel disease, and the days of hospitalization. We conclude that the determination of CRP levels provide a simple objective index of inflammatory activity with may be useful in the assessment, management and study of inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8452705

Source DB:  PubMed          Journal:  Rev Esp Enferm Dig        ISSN: 1130-0108            Impact factor:   2.086


  2 in total

1.  Does plasma resistin level have a role in predicting inflammatory bowel disease activity?

Authors:  N A Abdel Kader; F A Ali El-Din; E A A Khatab; N E ELAbd
Journal:  Indian J Gastroenterol       Date:  2010-06

Review 2.  C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis.

Authors:  Mahmoud H Mosli; Guangyong Zou; Sushil K Garg; Sean G Feagan; John K MacDonald; Nilesh Chande; William J Sandborn; Brian G Feagan
Journal:  Am J Gastroenterol       Date:  2015-05-12       Impact factor: 10.864

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.